Provided is a composition and method for delivery of bioactive agents to a cell or a subject. The composition includes nucleic acids derived from plants and the bioactive agents, and the nucleic acids are crossed linked by a cross-linking agent. Such composition is non-toxic, biocompatible and target specific. A method of making the composition is also provided.

The presently disclosed subject matter relates to the fields of pharmacology and medicine, and provides vaccine compositions and methods of use, particularly influenza compositions and methods of use to treat neonatal subjects.

A lipid membrane structure encapsulating an siRNA inside thereof and containing a lipid compound of the formula (I) as a lipid component (R.sup.1 and R.sup.2 represent CH.sub.3—(CH.sub.2).sub.n—CH═CH—CH.sub.2—CH═CH—(CH.sub.2).sub.m—, n represents an integer of 3 to 5, m represents an integer of 6 to 10, p represents an integer of 2 to 7, and R.sup.3 and R.sup.4 represent a C.sub.1-4 alkyl group or a C.sub.2-4 alkenyl group.

A vaccine RNA-peptide against SARS-CoV-2, which has a messenger ribonucleic acid (mRNA) having an open reading frame encoding a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein. The peptide of the severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein is fused to a synthetic poly ADP-ribose polymerase peptide. The vaccine RNA-peptide against SARS-CoV-2 has endogenous exosomes as carrier.

A nucleic acid molecule including at least one expression control sequence having an Internal Ribosomal Entry Site (IRES) sequence, at least one coding region, and optionally multiple adenosines or thymidines upstream of the at least one expression control sequence is disclosed as an expression system. Besides, a recombinant expression vector including the nucleic acid molecule and pharmaceutical or medicinal use of the nucleic acid molecule are disclosed.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and/or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.

In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and antigens bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle or icosahedron. The nanostructure design allows for control of the relative position and/or stoichiometry of the antigen bound to its surface. The antigens displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be an HIV immunogen such as eOD-GT6, eOD-GT8, or variants thereof. The compositions may thus be useful as immunogens, vaccines, immunostimulators, adjuvants, and the like. Methods of inducing immune responses, inducing protective immunity, inducing the production of neutralizing antibodies or inhibitory antibodies, inducing tolerance, and treating cancer, infectious or autoimmune diseases are also provided.

There are provided herein, inter alia, complexes, compositions and methods for the delivery of nucleic acid into a cell in vivo. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.

Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.